The Time Course of Development and Impact From Viral Resistance Against Ganciclovir in Cytomegalovirus Infection
| Autor: | Nikolai Kirkby, Jens D Lundgren, A. Cozzi Lepri, Finn Gustafsson, Allan Rasmussen, Maura D. Iversen, Casper M Frederiksen, Jesper Kjaer, Henrik Sengeløv, Søren Schwartz Sørensen, C. da Cunha-Bang, M. Sønderholm |
|---|---|
| Rok vydání: | 2013 |
| Předmět: |
Adult
Male Foscarnet Ganciclovir medicine.medical_specialty Time Factors Congenital cytomegalovirus infection Cytomegalovirus Gastroenterology Virus Inhibitory Concentration 50 Young Adult Recurrence Risk Factors Internal medicine Drug Resistance Viral Odds Ratio Prevalence medicine Humans Immunology and Allergy Pharmacology (medical) First episode Transplantation business.industry Hematopoietic Stem Cell Transplantation Absolute risk reduction virus diseases Organ Transplantation Odds ratio Middle Aged medicine.disease Phosphotransferases (Alcohol Group Acceptor) Treatment Outcome Cytomegalovirus Infections Mutation Immunology Female business medicine.drug |
| Zdroj: | American Journal of Transplantation. 13:458-466 |
| ISSN: | 1600-6135 |
| DOI: | 10.1111/ajt.12042 |
| Popis: | (Val)ganciclovir is used to treat cytomegalovirus (CMV) infection following solid organ (SOT) or hematopoietic stem cell (HSCT) transplantation. Treatment failures occur, but the contribution from 39 known ganciclovir-related mutations (GRMs) in the CMV-UL97 gene remains controversial. We propose a categorization of these GRMs potentially useful when interpreting sequence analyses in clinical settings. The UL97 gene was sequenced from first/recurrent CMV infections among consecutive SOT or HSCT recipients during 2004–2009. GRMs were categorized as: Signature GRM (sGRM) if in vitro ganciclovir IC50 ratio for mutated versus wild-type virus >2 (n = 24); polymorphic GRM (pGRM) if ratio |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Plný text